Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hebrew University of Jerusalem
Headquarters: Jerusalem, Israel
Website: http://new.huji.ac.il/en
Year Founded: 1918
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jan 11, 2025
Management Tracks
Faces in new places ahead of JPM: Rubin joining Guggenheim
Week’s management moves include new venture partners at Frazier and updates from Beigene, Intellia and more
BioCentury | Jan 7, 2025
Management Tracks
John Finn named CSO of Basecamp
Plus: Iambic hires Michael Secora and updates from Septerna, Beigene, Perspective, Halia and more
BioCentury | Apr 10, 2024
Emerging Company Profile
Moonwalk: Mapping the methylome to create epigenome editors
With CRISPR pioneer Feng Zhang among its founders, Moonwalk aims to control gene expression via epigenetic editing
BioCentury | Feb 9, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into infectious disease
Host targets, cross-reactive mAbs and COVID-19 countermeasures stand out in BioCentury’s Distillery
BioCentury | Nov 6, 2021
Emerging Company Profile
OncoHost: Personalizing cancer treatment based on host response
Israeli company analyzes proteomic changes after cancer treatment to identify resistance pathways and generate navigation system for clinicians
BioCentury | Sep 10, 2021
Targets & Mechanisms
Integrated stress response key to seemingly disparate diseases?
A flurry of preclinical studies builds the case for the integrated stress response as a central driver of many diseases
BioCentury | Aug 27, 2021
Distillery Therapeutics
Blocking unfolded protein response, integrated stress response for necrotizing fasciitis, lung cancer
BioCentury | Jul 30, 2021
Emerging Company Profile
Cytovia: activating NK cells at the tumor site
Emerging Company Profile: With its R&D center up and running and a manufacturing facility by year-end, Cytovia aims to enter the clinic early 2022
BioCentury | Feb 27, 2021
Translation in Brief
A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 94